Seoul National University

Kangwon National University Industry Cooperation Foundation

The Asan Foundation, University of Ulsan Foundation for Industry Cooperation

Catholic University Industry Academic Cooperation Foundation

Eugene C Yi

Min Jueng Kang

Ji Eun Kim

Donghyun Kim

Junho Chung

Jong Bae Park

Hyori Kim

Hwa Kyoung Lee

Junyeong Jin

Dongjin Jeong

Joo Youn Lee

Yeong Wook Song

Eunhee G Kim

Doo Hyun Chung

Kristine M Kim

Daehee Hwang

Yune Jung Park

Sung Youg You

Wan-Uk Kim

The present invention relates to a composition for preventing or treating diseases caused by overexpression of chemokine CXCL1 (fractalkine) comprising a death receptor 5 (DR5) inhibitor as an active ingredient, a method for preventing or treating diseases caused by overexpression of chemokine CXCL1 comprising administering a DR5 expression or activity inhibitor to a patient in need of prevention or treatment of diseases caused by overexpression of chemokine CXCL1 in a therapeutically effective amount, and a use for prevention or treatment of diseases caused by overexpression of chemokine CXCL1 of a DR5 expression or activity inhibitor.

Composition for preventing or treating diseases caused by overexpression of chemokine CXCL1, containing death receptor inhibitor as active ingredient

The present invention relates to an anti-ROS1 antibody improved in specificity for ROS1 and a use thereof and, more particularly, provides an anti-ROS1 antibody or an antigen-binding fragment thereof and a use thereof in cancer diagnosis.

Anti-ROS1 antibody and use thereof

A peptide for treating rheumatoid arthritis and use thereof are provided, and a peptide consisting of an amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 3, or SEQ ID NO: 5 or a polynucleotide encoding the same, and a pharmaceutical composition for treating rheumatoid arthritis or a health functional food composition for improving rheumatoid arthritis, each including the peptide, are provided.

Peptide for treating rheumatoid arthritis and use thereof

The present disclosure relates to a method for producing a monoclonal antibody that binds to an epitope for the glycan binding site of a glycoprotein. According to the present disclosure, a monoclonal antibody that recognizes the glycan binding site of a glycoprotein as an epitope can be produced in a relatively simple and economic manner, and a monoclonal antibody having high sensitivity and specificity for the glycan binding site of a glycoprotein can be produced. The monoclonal antibody produced according to the present disclosure can be effectively used as an agent for diagnosing or treating various diseases associated with a change in glycan structure or glycan expression level.

Methods for preparing monoclonal antibodies recognizing glycan binding site as an epitope

Growing community of inventors

Seoul, South Korea

Eugene C Yi